BACKGROUND AND OBJECTIVES: Previous in vitro studies have suggested that IGF-1 stimulation can lead a more aggressive breast cancers and subsequent poor prognosis in breast cancer patients. We aim to how IGF-1 and IGF-1R mRNA levels in breast cancer are associated with disease-free survival (DFS) and other clinicopathological factors. METHODS: IGF-1 and IGF-1R mRNA levels were measured in breast cancer tissue from 132 patients using real-time PCR. DFS and clinicopathological information were obtained from patient case notes. RESULTS: IGF-1 and IGF-1R mRNA levels did not correlate with any clinicopathological factors. Patients who relapsed had lower IGF-1 mRNA levels in their tumour tissue compared to those who remained disease-free during the 5-year follow-up period. Patients who had ER-positive breast cancers with high IGF-1 mRNA levels had longer DFS compared to those with low IGF-1 mRNA levels. IGF-1 mRNA levels was not associated with DFS in patients with ER-negative cancers. IGF-1R mRNA levels was not associated with DFS in any subgroup analysis. Multivariate analysis showed that IGF-1 mRNA levels and histopathological grade were independent predictors of DFS. CONCLUSIONS: Breast cancer tissue IGF-1 expression is a favourable prognostic indicator and could be used in clinical setting in planning for adjuvant treatment.
BACKGROUND AND OBJECTIVES: Previous in vitro studies have suggested that IGF-1 stimulation can lead a more aggressive breast cancers and subsequent poor prognosis in breast cancerpatients. We aim to how IGF-1 and IGF-1R mRNA levels in breast cancer are associated with disease-free survival (DFS) and other clinicopathological factors. METHODS:IGF-1 and IGF-1R mRNA levels were measured in breast cancer tissue from 132 patients using real-time PCR. DFS and clinicopathological information were obtained from patient case notes. RESULTS:IGF-1 and IGF-1R mRNA levels did not correlate with any clinicopathological factors. Patients who relapsed had lower IGF-1 mRNA levels in their tumour tissue compared to those who remained disease-free during the 5-year follow-up period. Patients who had ER-positive breast cancers with high IGF-1 mRNA levels had longer DFS compared to those with low IGF-1 mRNA levels. IGF-1 mRNA levels was not associated with DFS in patients with ER-negative cancers. IGF-1R mRNA levels was not associated with DFS in any subgroup analysis. Multivariate analysis showed that IGF-1 mRNA levels and histopathological grade were independent predictors of DFS. CONCLUSIONS:Breast cancer tissue IGF-1 expression is a favourable prognostic indicator and could be used in clinical setting in planning for adjuvant treatment.
Authors: Joseph A Ludwig; Salah-Eddine Lamhamedi-Cherradi; Ho-Young Lee; Aung Naing; Robert Benjamin Journal: Cancers (Basel) Date: 2011-07-26 Impact factor: 6.639
Authors: Danylo Rafhael Costa-Silva; Maria da Conceição Barros-Oliveira; Francisco Adelton Alves-Ribeiro; Larysse Cardoso Campos-Verdes; Elmo de Jesus Nery Junior; Samara Fernanda Vieira-Valença; Rodrigo Jose de Vasconcelos-Valença; Veronica Mendes Soares; André Luiz Pinho-Sobral; Emerson Brandão Sousa; Pedro Vitor Lopes-Costa; Alesse Ribeiro Dos Santos; Jackeline Lopes Viana; Arquimedes Cavalcante Cardoso; Victoria Maria Luz-Borges; Renato de Oliveira Pereira; Cleciton Braga Tavares; Vladimir Costa Silva; Dorival Mendes Rodrigues-Junior; Luiz Henrique Gebrim; Benedito Borges da Silva Journal: Medicine (Baltimore) Date: 2020-10-23 Impact factor: 1.817